NOVAVAX INC Fair Value, Assets, Level 2 to Level 1 Transfers, Amount
NOVAVAX INC (NVAX) had Fair Value, Assets, Level 2 to Level 1 Transfers, Amount of $0 as of 2020-09-30, per its 10-Q filed 2020-11-10.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount · last filed 2020-11-10
- 2020-09-30: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
| Period end | Fair Value, Assets, Level 2 to Level 1 Transfers, Amount |
|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |